Tumour M2-PK as a stool marker for colorectal cancer: Comparative analysis in a large sample of unselected older adults vs colorectal cancer patients

British Journal of Cancer

Volumn 96, Issue 9, 2007, Pages 1329-1334

  Haug, U ^a   Rothenbacher, D ^a   Wente, M N ^b   Seiler, C M ^b   Stegmaier, C ^c   Brenner, H ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c SAARLAND CANCER REGISTRY   (Germany)

Author keywords

Colorectal cancer; Diagnosis; Stool test; Tumour M2 PK

Indexed keywords

PYRUVATE KINASE; PYRUVATE KINASE ISOENZYME M 2; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; COLON CANCER; COLORECTAL CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FECES ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RECTUM CANCER; SAMPLE (STATISTICS); SENSITIVITY AND SPECIFICITY;

AGED; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; FECES; FEMALE; HUMANS; MALE; MIDDLE AGED; PYRUVATE KINASE; RECTAL NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 34247606814     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603712     Document Type: Article

References (21)

1. Brenner H (2002) Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet 360: 1131-1135
2. Brenner H, Stegmaier C, Ziegler H (2005) Long-term survival of cancer patients in Germany achieved by the beginning of the third millenium. Ann Oncol 16: 981-986
3. Ferlay J, Bray F, Pisani P, Parkin DM, GLOBOCAN 2002 (2004) Cancer Incidence, Mortality and Prevalence Worldwide IARC CancerBase No. 5. version 2.0, IARCPress, Lyon http://www-dep.iarc.fr/ (Accessed October 25 2005)
4. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, James PD, Mangham CM (1996) Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 348: 1472-1477
5. Hardt PD, Mazurek S, Toepler M, Schlierbach P, Bretzel RG, Eigenbrodt E, Kloer HU (2004) Faecal tumour M2 pyruvate kinase: a new, sensitive screening tool for colorectal cancer. Br J Cancer 91: 980-984
6. Haug U, Brenner H (2005a) New stool tests for colorectal cancer screening: A systematic review focusing on performance characteristics and practicalness. Int J Cancer 117: 169-176
7. Haug U, Brenner H (2005b) A simulation model for colorectal cancer screening: potential of stool tests with various performance characteristics compared to screening colonoscopy. Cancer Epidemiol Biomarkers Prev 14: 422-428
8. Haug U, Wente MN, Seiler CM, Rothenbacher D, Buchler MW, Brenner H (2006) Tumor M2 pyruvate kinase as a stool marker for colorectal cancer: stability at room temperature and implications for application in the screening setting. Clin Chem 52: 782-784
9. Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF (2000) Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N Engl J Med 343: 169-174
10. Koss K, Maxton D, Jankowski J (2005) The potential use of faecal dimeric M2 pyruvate kinase (tumour M2-PK) in screening for colorectal cancer. Gut 54: A20
11. Krebsregister Saarland. http://www.krebsregister.saarland.de/datenbank/ datenbank.html accessed November 20 (2006)
12. Mandel JS, Church TR, Ederer F, Bond JH (1999) Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst 91: 434-437
13. Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, Snover DC, Schuman LM (2000) The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 343: 1603-1607
14. Mazurek S, Grimm H, Boschek CB, Vaupel P, Eigenbrodt E (2002a) Pyruvate kinase type M2: a crossroad in the tumor metabolome. Br J Nutr 87(Suppl. 1): 23-29
15. Mazurek S, Luftner D, Wechsel HW, Schneider J, Eigenbrodt E (2002b) Tumor M2-PK: A marker of the tumor metabolome. In Tumor Markers: Physiology, Pathobiology, Technology, and Clinical Applications, Diamandis EP, Fritche HA, Lilja H, Chan DW, Schwartz MK (eds) pp 471-475. Washington, DC: AACC Press
16. Rex DK, Lehman GA, Ulbright TM, Smith JJ, Pound DC, Hawes RH, Helper DJ, Wiersema MJ, Langefeld CD, Li W (1993) Colonic neoplasia in asymptomatic persons with negative fecal occult blood tests: influence of age, gender, and family history. Am J Gastroenterol 88: 825-831
17. Rothenbacher D, Löw M, Hardt PD, Klor HU, Ziegler H, Brenner H (2005) Prevalence and determinants of exocrine pancreatic insufficiency among older adults: results of a population-based study. Scand J Gastroenterol 40: 697-704
18. Segnan N, Senore C, Andreoni B, Aste H, Bonelli L, Crosta C, Ferraris R, Gasperoni S, Penna A, Risio M, Rossini FP, Sciallero S, Zappa M, Atkins WS (2002) Baseline findings of the Italian multicenter randomized controlled trial of 'once-only sigmoidoscopy'-SCORE. J Natl Cancer Inst 94: 1743-1772
19. Shastri YM, Naumann M, Oremek GM, Hanisch E, Rosch W, Mossner J, Caspary WF, Stein JM (2006) Prospective multicenter evaluation of fecal tumor pyruvate kinase type M2 (M2-PK) as a screening biomarker for colorectal neoplasia. Int J Cancer 119: 2651-2656
20. Vatn MH, Stalsberg H (1982) The prevalence of polyps of the large intestine in Oslo: an autopsy study. Cancer 49: 819-825
21. Winawer SJ, Zauber A, Diaz B, O'Brien M, Gottlieb LS, Sternberg SS, Waye JD, Shike M (1988) The National Polyp Study: overview of program and preliminary report of patient and polyp characteristics. Prog Clin Biol Res 279: 35-49